The following is a sample of feedback that I have received recently.
From Jeffry F.
I support your application to the Canadian Federal Government to adopt ivermectin as a therapeutic under emergency use provisions to help save lives in this pandemic. The clinical evidence is overwhelmingly. We also support the FLCCC. How can I assist you?
I don't have much patience for politics and it appears to me the global
practise of diplomacy has eroded to non-existence. Science should be
the deciding factor and the existing IVM clinical reports are
demonstrably conclusive. Ōmura Satoshi's report published last week
should be front page news yet no one is talking about it and its hard to
find even with a google search. Have you read his latest release?
http://jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf.
From Ondrej H.
Thank you very much for arranging the ivermectin petition. My name is Ondrej H. and I work at University of Toronto. Over the past few months I have been promoting the use of ivermectin for the treatment of Covid-19. I have been able to get in touch with researchers in Australia, many leading doctors in US and some doctors in Europe. I'm originally from Slovakia. Me and others have been able to make ivermectin available there - maybe you saw that Slovakia became the 1st EU country to approve ivermectin for both prophylaxis and treatment of Covid-19. It has subsequently been widely discussed in the neighboring Czech Republic too.
In March, Czech Republic purchased ivermectin for 20,000 patients.
From Joanne S.
I have sent petition to all friends and family with this note along other information about Ivermectin: “This is a petition to the House of Commons initiated by a Professor Emeritus at Queens University, Kanji Nakatsu. His endorsement of Ivermectin, after a 44-year career as a professor of pharmacology and toxicology, is additional assurance to me of both the utility and the safety of this drug.”
... politicians don’t realize they could be heroes if they supported and facilitated this initiative has been one of the biggest puzzles of all to me in the pandemic. I’ve sent letters and emails to dozens of them suggesting this.
From: Carolina Venditti
To:Premier Doug Ford, Minister of Health Christine Elliott, Prime Minister Justin Trudeau, Minister of Health Patty Hajdu, NDP Leader Jagmeet Singh, PC Leader Erin O'Toole, MP Mark Gerretson, MP Dean Allison
I am writing this letter in support of the use of ivermectin, both as a prophylaxis and as a treatment for COVID-19. As a mother of two young children and the wife of a front-line worker, it is frustrating and infuriating to know that there is currently a medication which could not only treat persons with COVID-19, but also be of use prophylactically, and yet this medication (i.e., ivermectin) is not being made readily available to all Canadians.
With a doctorate in Biomedical and Molecular Sciences, I understand the information presented in scientific publications (of which there are MANY), which describe both ivermectin’s safety [i.e., ivermectin is approved by the United States Food and Drug Administration and by Health Canada as an anti-parasitic drug and has been used for years to treat billions of persons globally, for example those diagnosed with scabies or malaria (reviewed by Kircik et al., 2016)] and its efficacy [i.e., randomized controlled trials, systematic reviews and many case reports have shown that this anti-parasitic drug displays anti-viral and anti-inflammatory properties which can effectively treat persons diagnosed with COVID-19 (Carvallo et al., 2020; Elgazzar et al., 2020; Gorial et al., 2020; Hashim et al., 2020; Khan et al., 2020; Mahmud, 2020; Morgenstern et al., 2020; Niaee et al., 2020; Portmann-Baracco et al., 2020; Rajter et al., 2020; Robin et al., 2020; Spoorthi V, 2020 and reviewed in Kory et al., 2020)]. While the data are unquestionably compelling and substantiate the use of ivermectin as a treatment for COVID-19, you certainly do not need to read my reiteration of the information, which has so clearly been presented time and time again by numerous scientists, doctors and prominent scientific groups, including the FLCCC Alliance (Available at: https://covid19criticalcare.com/ivermectin-in-covid-19/).
The use of ivermectin to treat patients diagnosed with COVID-19 is not a new concept. Brave doctors globally have been prescribing this medication over the course of this past year as an attempt to combat the effects of the pandemic. Data are available to show that, in countries where ivermectin has been provided to patients diagnosed with COVID-19, death rates due to the virus have dropped immensely [e.g., several states in Argentina, the state of Alto Parana in Paraguay, the state of Uttar Pradesh in India (reviewed by Juan Chamiea) and in Peru (Chamie, 2020)].
In Canada, when diagnosed with COVID-19, people are sent home with no recourse. Patients are returning to the hospital when the effects of the virus have worsened (e.g., they cannot breathe easily on their own); burdening our healthcare system, specifically the hospitals and their intensive care units. It is evident that we require some form of early home treatment. Even without the evidence from large, multi-centre efficacy trials, we should be using ivermectin as a treatment option.
I urge you to review the data. I urge you to provide this cheap, safe and highly effective medication to all Canadians for the treatment of COVID-19. I, like many others I know, have purchased food-grade veterinary ivermectin, should the need arise for my family to use it; we should not need to do this.
Thank you,
C. Venditti
Ph.D., Biomedical and Molecular Sciences Concerned Canadian mother of two and wife of a front-line worker
a Available at: https://covid19criticalcare.com/ivermectin-in-covid-19/epidemiologic-analyses-on-covid19-and-ivermectin/
References:
Carvallo, H.E., Hirsch, R.R., and Farinella, M.E. (2020). Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv.
Chamie, J. (2020). Real-World Evidence: The Case of Peru. Causality between Ivermectin and
COVID-19 Infection Fatality Rate.
Elgazzar, A., Hany, B., Youssef, S.A., Hafez, M., and Moussa, H. (2020). Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic.
Gorial, F.I., Mashhadani, S., Sayaly, H.M., Dakhil, B.D., Almashhadani, M.M., Aljabory, A.M., Abbas, Hassan M, Ghanim, M., and Rasheed, J.I. (2020). Effectiveness of Ivermectin as add on Therapy in COVID-19 Management (Pilot Trial). medRxiv.
Hashim, H.A., Maulood, M.F., Rasheed, A.M., Fatak, D.F., Kabah, K.K., and Abdulamir, A.S. (2020). Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv.
Khan, M.S.I., Khan, M.S.I., Debnath, C.R., Nath, P.N., Mahtab, M.A., Nabeka, H., Matsuda, S., and Akbar, S.M.F. (2020). Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Archivos de Bronconeumología
Kircik, L.H., Del Rosso, J.Q., Layton, A.M., and Schauber, J. (2016). Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. Journal of drugs in dermatology : JDD 15, 325-332
Kory, P., MD, Meduri, G. U., MD, Iglesias, J., Varon, J., Berkowitz, K., MD, Kornfeld, H., MD, Vinjevoll, E., MD, Mitchell, S., MBChB, Wagshul, F., MD, and Marik, P. E. (2020). Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. https://doi.org/10.31219/osf.io/wx3zn
Morgenstern, J., Redondo, J.N., De Leon, A., Canela, J.M., Torres, N., Tavares, J., Minaya, M., Lopez, O., Placido, A.M., and Castillo, A. (2020). The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. medRxiv
Niaee, M.S., Gheibi, N., Namdar, P., Allami, A., Zolghadr, L., Javadi, A., Karampour, A., Varnaseri, M., Bizhani, B., and Cheraghi, F. (2020). Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial.
Portmann-Baracco, A., Bryce-Alberti, M., and Accinelli, R.A. (2020). Antiviral and Anti Inflammatory Properties of Ivermectin and Its Potential Use in Covid-19. Arch Bronconeumol.
Rajter, J.C., Sherman, M.S., Fatteh, N., Vogel, F., Sacks, J., and Rajter, J.J. (2020). Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study). Chest.
Robin, R.C., Alam, R.F., Saber, S., Bhiuyan, E., Murshed, R., and Alam, M.T. (2020). A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons, 10-15.
Spoorthi V, S.S. (2020). Utility of Ivermectin and Doxycycline combination for the treatment of SARS-CoV2. International Archives of Integrated Medicine 7, 177-182.
From Donna Klay
Hello Dr. Nakatsu,
No comments:
Post a Comment